Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains.
暂无分享,去创建一个
[1] T. C. White,et al. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans , 1997, Antimicrobial agents and chemotherapy.
[2] Brian C. Baldwin,et al. The Mutation T315A in Candida albicans Sterol 14α-Demethylase Causes Reduced Enzyme Activity and Fluconazole Resistance through Reduced Affinity* , 1997, The Journal of Biological Chemistry.
[3] J. Martínez-Suárez,et al. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] R. Cannon,et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance , 1996, Antimicrobial agents and chemotherapy.
[5] H. Nakagawa,et al. Tacrolimus Has Antifungal Activities against Malassezia furfur Isolated from Healthy Adults and Patients with Atopic Dermatitis , 1996 .
[6] D. Sanglard,et al. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors , 1996, Antimicrobial agents and chemotherapy.
[7] W. Dalton,et al. Resistance to the chemosensitizer verapamil in a multi‐drug‐resistant (MDR) human multiple myeloma cell line , 1996, International journal of cancer.
[8] R. Collins,et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. , 1996, Blood.
[9] W T Bellamy,et al. P-glycoproteins and multidrug resistance. , 1996, Annual review of pharmacology and toxicology.
[10] K. Kuchler,et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.
[11] B. Althaus,et al. Antifungal Prophylaxis in Bone Marrow Transplant , 1995, The Annals of pharmacotherapy.
[12] P. Marichal,et al. Origin of differences in susceptibility of Candida krusei to azole antifungal agents , 1995, Mycoses.
[13] A. Oppenheim,et al. Multidrug resistance in Candida albicans: disruption of the BENr gene , 1995, Antimicrobial agents and chemotherapy.
[14] P. Marichal,et al. Mechanisms of resistance to azole antifungals. , 1995, Acta biochimica Polonica.
[15] F. Odds,et al. Molecular mechanisms of drug resistance in fungi. , 1994, Trends in microbiology.
[16] P. Rathod,et al. Loss of function mutation in the yeast multiple drug resistance gene PDR5 causes a reduction in chloramphenicol efflux , 1994, Antimicrobial Agents and Chemotherapy.
[17] J. Ordonez,et al. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. , 1993, Blood.
[18] Y. Tanigawara,et al. Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.
[19] I. Pastan,et al. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[20] B. Bierer,et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. , 1992, Blood.
[21] J. Lankelma,et al. Induction by verapamil of a rapid increase in ATP consumption in multidrug‐resistant tumor cells , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.